Please assess the completion status of the following clinical trial:

Trial Title: Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy, adult subjects, 18 years and older~* able to swallow medication~Exclusion Criteria:~* institutionalized subjects~* history of any significant disease~* use of any prescription or OTC medications within 14 days of start of study~* received any investigational products within 30 days prior to start of study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Olanzapine Tablets 20 mg
- 2 (Type: ACTIVE_COMPARATOR): Zyprexa® Tablets 20 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).